Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Radioimmunotherapy allows doctors to target radiation to specific sites. The technology links radioactive atoms to monoclonal antibodies that deliver the radioactivity by seeking out and latching onto proteins found on cancer cells.
This type of therapy allows doctors to concentrate radiation at tumor sites, reducing the amount of radiation that reaches healthy tissue.
Radioimmunotherapy treatment at Stanford
Stanford researchers are leaders in the field of radioimmunotherapy, and doctors at the Stanford Cancer Center have been very active in clinical trials of this promising technology.
Patients with non-Hodgkin's B-cell lymphoma, leukemia, prostate, colorectal and pancreatic cancers, and soft tissue sarcomas have all received radioimmunotherapy through trials at Stanford.
Additional clinical trials continue to be initiated. Your doctor can help you find trials and determine if it is appropriate to include radioimmunotherapy in your treatment plan.